Table 1.
Baseline characteristics of the included studies.
| Author | Year | Country | Patients, no | Mean age, years | Mean follow‐up, months | Number of recurrences | Number of metastases | Minors score |
|---|---|---|---|---|---|---|---|---|
| Ang | 2009 | USA | 86 | 71.8 | 82.8 | 2 | 0 | 11 |
| Beer | 2010 | Australia | 167 | 75.1 | 56.9 | 2 | 0 | 11 |
| Davidson | 2012 | Canada | 71 | 76.4 | 68.5 | 7 | 3 | 12 |
| Flohil | 2017 | Netherlands | 22 | 71.8 | 24.0 | 2 | 0 | 13 |
| Hudson | 1972 | USA | 15 | 52.3 | 18.5 | 0 | 0 | 7 |
| Iglesias‐Pena | 2020 | Spain | 62 | 81.0 | 47.7 | 4 | 0 | 14 |
| Kempson | 1964 | USA | 19 | 66.3 | 90.5 | 2 | 0 | 13 |
| Koch | 2015 | Germany | 18 | 75.4 | 53.8 | 4 | 1 | 12 |
| Limmer | 1997 | USA | 6 | 71.5 | 32.5 | 0 | 0 | 8 |
| Seavolt | 2006 | USA | 11 | 75.1 | 29.5 | 0 | 0 | 8 |
| Sloane | 2015 | UK | 48 | 79.9 | 26.8 | 9 | 0 | 10 |
| Thum | 2013 | UK | 8 | 75.6 | 52.8 | 0 | 0 | 11 |
| Wollina | 2015 | Germany | 50 | 78.7 | 13.0 | 2 | 4 | 9 |
| Wylie | 2010 | UK | 15 | 80.4 | 30.5 | 1 | 0 | 8 |